BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34953233)

  • 21. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
    Bonfitto VL; de Angelo Andrade LA
    Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.
    Kreizman-Shefer H; Pricop J; Goldman S; Elmalah I; Shalev E
    Diagn Pathol; 2014 Mar; 9():77. PubMed ID: 24684970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
    Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
    Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
    Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
    [No Abstract]   [Full Text] [Related]  

  • 26. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
    Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
    Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.
    AlHilli MM; Podratz KC; Dowdy SC; Bakkum-Gamez JN; Weaver AL; McGree ME; Keeney GL; Cliby WA; Mariani A
    Gynecol Oncol; 2013 Oct; 131(1):103-8. PubMed ID: 23845691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.
    Obata T; Nakamura M; Mizumoto Y; Iizuka T; Ono M; Terakawa J; Daikoku T; Fujiwara H
    PLoS One; 2017; 12(11):e0188641. PubMed ID: 29190668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
    Li M; Zhao L; Shen D; Li X; Wang J; Wei L
    Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.
    Obeidat BR; Matalka II; Mohtaseb AA; Al-Kaisi NS
    Pathol Oncol Res; 2013 Apr; 19(2):229-35. PubMed ID: 23055021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does tumor size have prognostic value in patients undergoing lymphadenectomy in endometrioid-type endometrial cancer confined to the uterine corpus?
    Çakır C; Kılıç İÇ; Yüksel D; Karyal YA; Üreyen I; Boyraz G; Durmuş Y; Gültekin M; Özgül N; Karalök MA; Salman MC; Yüce K; Turan AT
    Turk J Med Sci; 2019 Oct; 49(5):1403-1410. PubMed ID: 31650820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
    Han KH; Kim HS; Lee M; Chung HH; Song YS
    Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
    de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
    PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrence patterns and prognostic factors in lymphovascular space invasion-positive endometrioid endometrial cancer surgically confined to the uterus.
    Sahin H; Meydanli MM; Sari ME; Kocaman E; Cuylan ZF; Yalcin I; Coban G; Özen Ö; Sirvan L; Güngör T; Ayhan A
    Taiwan J Obstet Gynecol; 2019 Jan; 58(1):82-89. PubMed ID: 30638487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
    Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.
    Mauland KK; Trovik J; Wik E; Raeder MB; Njølstad TS; Stefansson IM; Oyan AM; Kalland KH; Bjørge T; Akslen LA; Salvesen HB
    Br J Cancer; 2011 Mar; 104(6):921-6. PubMed ID: 21343929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of body mass index with ER, PR and 14-3-3σ expression in tumor and stroma of type I and type II endometrial carcinoma.
    Peevey JF; Seagle BL; Maniar KP; Kim JJ
    Oncotarget; 2017 Jun; 8(26):42548-42559. PubMed ID: 28476021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation between estrogen receptor status and clinicopathologic parameters in endometrial cancer: a comparative study by immunohistochemistry using different scoring systems].
    Wang Y; Ma XL; Xi CG; Lin J; Ren CX; Liu CR
    Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):509-14. PubMed ID: 24246914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.